KRAS and colorectal carcinoma: While our findings support previous studies highlighting the persistence of known clinically-relevant mutations between primary and metastatic CRC lesions10,11, we showed that, when present in the primary tumor, clinically-relevant KRAS and NRAS mutations are transmitted to the metastatic lesions of different organs and likely represent ubiquitous driver mutations43.